Spartalizumab in Combination With Dabrafenib And Trametinib in Advanced BRAF V600–Mutant Melanoma: Efficacy, Safety, and Biomarker Findings in Parts 1 and 2 of COMBI-i

While recent 5-year analyses of Phase III trials in metastatic melanoma have demonstrated that checkpoint inhibitors and targeted therapy lead to long-term survival, many patients experience progression and novel treatment strategies are needed. In parts 1 and 2 of COMBI-i (NCT02967692), spartalizumab + dabrafenib + trametinib demonstrated an objective response rate of 78% (95% CI, 61%-90%) and a complete response rate of 44%. Additionally, exploratory biomarker identified baseline biomarkers as well as on-treatment modulations that may predict patients likely to achieve long-term benefit.